Indivior Pharmaceuticals (INDV) Gains from Investment Securities (2024 - 2025)

Indivior Pharmaceuticals (INDV) recorded quarterly Gains from Investment Securities of -$3.0 million in Q4 2025, down 175.0% quarter-over-quarter from $4.0 million in Q2 2025, and down 250.0% on a YoY basis from $2.0 million in Q4 2024.

Indivior Pharmaceuticals (INDV) Gains from Investment Securities (2024 - 2025) Analysis & Trends

Indivior Pharmaceuticals' Gains from Investment Securities history runs 2 years deep, the most recent figure standing at -$3.0 million for Q4 2025.

  • In Q4 2025, Gains from Investment Securities fell 250.0% year-over-year to -$3.0 million; the TTM figure through Mar 2026 stood at $1.0 million (down 95.45% YoY), while the FY2024 annual figure was $22.0 million, changed 0.0% from the prior year.
  • Gains from Investment Securities was -$3.0 million for Q4 2025 at Indivior Pharmaceuticals, down from $4.0 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $21.0 million in Q2 2024 to a low of -$3.0 million in Q4 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Teva Pharmaceutical Industries 38.77 Bn 35.04 Bn 1.97 Bn
2 Zoetis 34.11 Bn 32.16 Bn 1.62 Bn
3 United Therapeutics 23.68 Bn 21.53 Bn 648.10 Mn
4 Aurora Cannabis 16.48 Bn 16.40 Bn 33.43 Mn
5 Neurocrine Biosciences 16.19 Bn 14.88 Bn 800.70 Mn
6 Elanco Animal Health 11.44 Bn 11.01 Bn 785.00 Mn
7 Alkermes 7.28 Bn 6.77 Bn -116.06 Mn
8 Lantheus Holdings 6.48 Bn 5.98 Bn 230.92 Mn
9 Hims & Hers Health 6.35 Bn 5.60 Bn 396.79 Mn
10 Indivior Pharmaceuticals - - 277.00 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -3.00 Mn
Dec 31, 2025 -3.00 Mn
Jun 30, 2025 4.00 Mn
Jun 30, 2025 4.00 Mn
Mar 31, 2025 -1.00 Mn
Mar 31, 2025 -1.00 Mn
Dec 31, 2024 2.00 Mn
Dec 31, 2024 2.00 Mn
Jun 30, 2024 21.00 Mn
Jun 30, 2024 21.00 Mn
Mar 31, 2024 -1.00 Mn
Mar 31, 2024 -1.00 Mn